

Financial Statements of

**ARTHRITIS SOCIETY CANADA/
SOCIÉTÉ D'ARTHRITE DU
CANADA**

And Independent Auditor's Report thereon

Year ended March 31, 2025

**KPMG LLP**

Vaughan Metropolitan Centre
100 New Park Place, Suite 1400
Vaughan, ON L4K 0J3
Canada
Telephone 905 265 5900
Fax 905 265 6390

INDEPENDENT AUDITOR'S REPORT

To the Board of Directors of Arthritis Society Canada/Société d'Arthrite du Canada

Qualified Opinion

We have audited the financial statements of Arthritis Society Canada/Société d'Arthrite du Canada (the Entity), which comprise:

- the statement of financial position as at March 31, 2025
- the statement of financial activities for the year then ended
- the statement of changes in resources for the year then ended
- the statement of cash flows for the year then ended
- and notes to the financial statements, including a summary of significant accounting policies

(Hereinafter referred to as the "financial statements").

In our opinion, except for the possible effects of the matter described in the **"Basis for Qualified Opinion"** section of our auditor's report, the accompanying financial statements present fairly, in all material respects, the financial position of the Entity as at March 31, 2025, and its results of operations and its cash flows for the year then ended in accordance with Canadian accounting standards for not-for-profit organizations.

Basis for Qualified Opinion

In common with many charitable organizations, the Entity derives revenue from support from the public, the completeness of which is not susceptible to satisfactory audit verification. Accordingly, verification of this revenue was limited to the amounts recorded in the records of the Entity.

Therefore, we were not able to determine whether any adjustments might be necessary to:

- the current assets reported in the statements of financial position as at March 31, 2025 and March 31, 2024
- the contributions and excess (deficiency) of revenue over expenses reported in the statements of financial activities for the years ended March 31, 2025 and March 31, 2024



Page 2

- the resources, at the beginning and end of the year, reported in the statements of changes in resources for the years ended March 31, 2025 and March 31, 2024
- the excess (deficiency) of revenue over expenses reported in the statements of cash flows for the years ended March 31, 2025 and March 31, 2024.

Our opinion on the financial statements for the year ended March 31, 2024 was qualified accordingly because of the possible effects of this limitation in scope.

We conducted our audit in accordance with Canadian generally accepted auditing standards. Our responsibilities under those standards are further described in the **"Auditor's Responsibilities for the Audit of the Financial Statements"** section of our auditor's report.

We are independent of the Entity in accordance with the ethical requirements that are relevant to our audit of the financial statements in Canada and we have fulfilled our other ethical responsibilities in accordance with these requirements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our qualified opinion.

Other Information

Management is responsible for the other information. Other information comprises:

- the information, other than the financial statements and the auditor's report thereon, included in the Annual Report 2025.

Our opinion on the financial statements does not cover the other information and we do not and will not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information identified above and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit and remain alert for indications that the other information appears to be materially misstated.

We obtained the information, other than the financial statements and the auditor's report thereon, included in the Annual Report 2025 as at the date of this auditor's report.

If, based on the work we have performed in this other information, we conclude that there is a material misstatement of this other information, we are required to report that fact in the auditor's report.

We have nothing to report in this regard.



Responsibilities of Management and Those Charged with Governance for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with Canadian accounting standards for not-for-profit organizations, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Entity's ability to continue as a going concern, disclosing as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Entity or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Entity's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion.

Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Canadian generally accepted auditing standards will always detect a material misstatement when it exists.

Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the financial statements.

As part of an audit in accordance with Canadian generally accepted auditing standards, we exercise professional judgment and maintain professional skepticism throughout the audit.

We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion.

The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Entity's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.



Page 4

- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Entity's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Entity to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
- Communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

A handwritten signature in black ink that reads 'KPMG LLP'. The signature is written in a cursive, stylized font and is underlined with a single horizontal stroke.

Chartered Professional Accountants, Licensed Public Accountants

Vaughan, Canada

June 13, 2025

ARTHRITIS SOCIETY CANADA/ SOCIÉTÉ D'ARTHRITE DU CANADA

Statement of Financial Position

March 31, 2025, with comparative information for 2024


	2025	2024
Assets		
Current assets:		
Cash	\$ 344,826	\$ 712,644
Restricted cash	6,038	31,825
Short-term investments (note 2(a))	554,859	216,752
Accounts receivable	591,347	816,711
Prepaid expenses	1,015,720	1,119,790
	<u>2,512,790</u>	<u>2,897,722</u>
Long-term investments (note 2(b))	4,466,396	3,722,824
Capital assets (note 3)	2,178,663	2,116,468
Asset held for sale (note 15)	—	383,056
	<u>\$ 9,157,849</u>	<u>\$ 9,120,070</u>

Liabilities and Resources

Current liabilities:		
Bank indebtedness (note 12)	\$ —	\$ 1,760,000
Accounts payable and accrued liabilities	1,481,614	1,001,225
Deferred revenue	570,264	451,262
Research awards payable (note 11)	689,726	1,162,307
	<u>2,741,604</u>	<u>4,374,794</u>
Deferred capital grants and donations (note 4)	563,451	609,617
Deferred contributions (note 5)	2,491,554	833,670
	<u>5,796,609</u>	<u>5,818,081</u>
Resources	3,361,240	3,301,989
Commitments (notes 9 and 10)		
	<u>\$ 9,157,849</u>	<u>\$ 9,120,070</u>

See accompanying notes to financial statements.

On behalf of the Board:

 Director

 Director

ARTHRITIS SOCIETY CANADA/ SOCIÉTÉ D'ARTHRITE DU CANADA

Statement of Financial Activities

Year ended March 31, 2025, with comparative information for 2024

	2025	2024
Revenue:		
Support from the public:		
Campaigns	\$ 15,469,285	\$ 14,190,933
Bequests and other planned giving	4,613,175	6,866,761
	20,082,460	21,057,694
Investment, rental and miscellaneous	1,844,410	2,224,003
Support from government departments and agencies	5,930,795	7,356,140
Total revenue	27,857,665	30,637,837
Expenses (note 13):		
Research	7,031,652	6,558,865
Programs and services	11,744,127	11,799,527
Building operation	718,532	807,915
Administration	3,139,458	3,161,659
	22,633,769	22,327,966
Cost of raising funds from the public (note 13)	9,888,114	9,391,484
Total expenses	32,521,883	31,719,450
Deficiency of revenue over expenses before the undernoted	(4,664,218)	(1,081,613)
Gain on sale of property	4,703,302	—
Unrealized gain (loss) on investments	14,709	(44,589)
	4,718,011	(44,589)
Excess (deficiency) of revenue over expenses	\$ 53,793	\$ (1,126,202)

See accompanying notes to financial statements.

ARTHRITIS SOCIETY CANADA/ SOCIÉTÉ D'ARTHRITE DU CANADA

Statement of Changes in Resources

Year ended March 31, 2025, with comparative information for 2024

	2025			2024	
	Unappropriated	Endowments	Invested in capital assets	Total	Total
Resources, beginning of year	\$ (962,816)	\$ 2,374,900	\$ 1,889,905	\$ 3,301,989	\$ 4,423,191
Excess (deficiency) of revenue over expenses	319,177	–	(265,384)	53,793	(1,126,202)
Sale of property (note 15)	383,056	–	(383,056)	–	–
Additions to capital assets	(373,747)	–	373,747	–	–
Endowment contributions and changes	(4,365)	9,823	–	5,458	5,000
Resources, end of year	\$ (638,695)	\$ 2,384,723	\$ 1,615,212	\$ 3,361,240	\$ 3,301,989

See accompanying notes to financial statements.

ARTHRITIS SOCIETY CANADA/ SOCIÉTÉ D'ARTHRITE DU CANADA

Statement of Cash Flows

Year ended March 31, 2025, with comparative information for 2024

	2025	2024
Cash provided by (used in):		
Operating activities:		
Excess (deficiency) of revenue over expenses	\$ 53,793	\$ (1,126,202)
Items not affecting cash:		
Amortization of deferred capital grants and donations	(46,166)	(66,750)
Amortization of deferred contributions	(826,119)	(3,312,652)
Amortization of deferred lease inducements	—	(50,803)
Amortization of capital assets	311,552	327,240
Change in unrealized loss (gain) on investments	(14,709)	44,589
Gain on sale of property	(4,703,302)	—
Change in non-cash operating working capital (note 7)	456,244	(984,427)
	(4,768,707)	(5,169,005)
Financing activities:		
Deferred contributions received	2,484,003	892,995
Net endowment contributions and changes	5,458	5,000
Increase (decrease) in bank indebtedness	(1,760,000)	1,760,000
	729,461	2,657,995
Investing activities:		
Net sale (purchase) of investments	(1,066,970)	3,356,604
Net purchases of capital assets	(373,747)	(741,257)
Proceeds on sale of property	5,086,358	—
	3,645,641	2,615,347
Increase (decrease) in cash	(393,605)	104,337
Cash, beginning of year	744,469	640,132
Cash, end of year	\$ 350,864	\$ 744,469
Represented by:		
Cash	\$ 344,826	\$ 712,644
Restricted cash	6,038	31,825
	\$ 350,864	\$ 744,469

See accompanying notes to financial statements.

ARTHRITIS SOCIETY CANADA/ SOCIÉTÉ D'ARTHRITE DU CANADA

Notes to Financial Statements

Year ended March 31, 2025

Arthritis Society Canada/Société d'Arthrite du Canada (the "Society") is incorporated without share capital under the Canada Corporations Act and was continued under the Canada Not-for-Profit Corporations Act in July 2013. The Society is a charitable organization registered under the Income Tax Act (Canada) and, as such, it is exempt from income taxes and is able to issue donation receipts for income tax purposes.

The mission of the Society is fight the fire of arthritis with research, advocacy, innovation, information and support.

1. Significant accounting policies:

The financial statements have been prepared by management in accordance with Canadian accounting standards for not-for-profit organizations ("ASNPO") in Part III of the Chartered Professional Accountants of Canada Handbook.

(a) Basis of presentation:

These financial statements include the assets, liabilities, revenue and expenses of the regions and the National Office of the Society.

(b) Revenue recognition:

The Society follows the deferral method of accounting. Under the deferral method, contributions related to expenses of future periods are recorded as deferred contributions and are recognized as revenue in the year in which the related expenses are incurred. Unrestricted contributions are recognized as revenue when received or receivable if the amount to be received can be reasonably estimated and collection is reasonably assured.

Endowment contributions are shown on the statement of changes in resources.

ARTHRITIS SOCIETY CANADA/ SOCIÉTÉ D'ARTHRITE DU CANADA

Notes to Financial Statements (continued)

Year ended March 31, 2025

1. Significant accounting policies (continued):

(c) Allocation of expenses:

Expenses are recorded and reported by programs and services. Certain employees perform a combination of program, fundraising and administrative functions; as a result, salaries and benefits are allocated based on time dedicated to the functional activities. Other costs, including amortization of capital assets and executive office and administrative support, are allocated to the programs and services that benefit from the activities. Such allocations are reviewed regularly by management.

(d) Financial instruments:

Financial instruments are recorded at fair value on initial recognition. Equity instruments that are quoted in an active market are subsequently measured at fair value. All other financial instruments are subsequently recorded at cost or amortized cost unless management has elected to carry the instruments at fair value. The Society has elected to carry any such financial instruments at fair value.

Transaction costs incurred on the acquisition of financial instruments measured subsequently at fair value are expensed as incurred. All other financial instruments are adjusted by transaction costs incurred on acquisition and financing costs, which are amortized using the straight-line method.

Financial assets are assessed for impairment on an annual basis at the end of the fiscal year if there are indicators of impairment. If there is an indicator of impairment, the Society determines if there is a significant adverse change in the expected amount or timing of future cash flows from the financial asset. If there is a significant adverse change in the expected cash flows, the carrying value of the financial asset is reduced to the highest of the present value of the expected cash flows, the amount that could be realized from selling the financial asset or the amount the Society expects to realize by exercising its right to any collateral. If events and circumstances reverse in a future period, an impairment loss will be reversed to the extent of the improvement, not exceeding the initial carrying value.

ARTHRITIS SOCIETY CANADA/ SOCIÉTÉ D'ARTHRITE DU CANADA

Notes to Financial Statements (continued)

Year ended March 31, 2025

1. Significant accounting policies (continued):

(e) Resources balances:

Unappropriated resources record the general activities of the Society.

Invested in capital assets reflect that portion of the Society's resources that relate to capital assets. These resources will increase for capital asset purchases, reductions in capital lease obligations, amortization of deferred capital grants and donations directly related to capital assets, and will be reduced by amortization charges, the net book value of capital asset disposals, increases in capital lease obligations and increases in deferred capital grants and donations.

Endowment funds are externally restricted donations received by the Society where the endowment principal is required to be maintained intact. The investment income generated from these endowments is to be used in accordance with the various purposes established by the donors. The Society ensures that all funds received with a restricted purpose are expended for the purpose for which they were provided.

(f) Research awards payable:

These financial statements reflect grants made during the year, which became effective at different dates during the year. The balance of these grants remaining payable at year end is included as research awards payable on the statement of financial position.

(g) Capital assets:

Purchased capital assets are recorded at cost. Donated capital assets are recorded at fair value at the date of contribution. Repairs and maintenance costs are charged to expense. Betterments which extend the estimated life of an asset are capitalized.

ARTHRITIS SOCIETY CANADA/ SOCIÉTÉ D'ARTHRITE DU CANADA

Notes to Financial Statements (continued)

Year ended March 31, 2025

1. Significant accounting policies (continued):

Amortization is provided on a straight-line basis over the estimated useful lives of the assets and is recorded beginning in the month of acquisition as follows:

Buildings	5%
Computer equipment and software	33.33%
Furniture and equipment	20%
Leasehold improvements	Over term of lease

Capital assets are written down to fair value or replacement cost to reflect partial impairments when conditions indicate that the assets no longer contribute to the Society's ability to provide services, or that the value of future economic benefits or service potential associated with the capital assets are less than their net carrying amounts.

(h) Deferred capital grants and donations:

Government grants and donations received for the purpose of capital purchases are deferred and amortized over the expected useful life of the asset to which the grants and donations relate.

(i) Deferred lease inducements:

Deferred lease inducements represent leasehold improvements on account of capital expenditures financed by the landlord. These lease inducements are amortized on a straight-line basis over the term of the lease and are recorded as a reduction in rental expense.

(j) Contributed services:

Volunteers contribute countless hours each year to assist the Society in achieving its mission. Because of the difficulty in determining their fair value, contributed services are not recognized in the financial statements.

ARTHRITIS SOCIETY CANADA/ SOCIÉTÉ D'ARTHRITE DU CANADA

Notes to Financial Statements (continued)

Year ended March 31, 2025

1. Significant accounting policies (continued):

(k) Use of estimates:

The preparation of financial statements in conformity with ASNPO requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the year. Actual results could differ from those estimates.

2. Investments:

(a) Short-term investments include:

	2025	2024
Fixed income	\$ 492,201	\$ 34,638
Money market	60,695	147,774
Equity pooled fund	1,963	5,912
Fixed income pooled fund	—	28,428
	<u>\$ 554,859</u>	<u>\$ 216,752</u>

Short-term fixed-income funds have maturity dates of less than a year from the statement of financial position dates and bear interest at rates ranging from 2.09% to 5.80% (2024 - 1.25% to 8.35%).

(b) Long-term investments include:

	2025	2024
Fixed income	\$ 3,175,366	\$ 1,979,539
Equity pooled funds	386,458	839,636
Fixed income pooled fund	904,572	903,649
	<u>\$ 4,466,396</u>	<u>\$ 3,722,824</u>

ARTHRITIS SOCIETY CANADA/ SOCIÉTÉ D'ARTHRITE DU CANADA

Notes to Financial Statements (continued)

Year ended March 31, 2025

2. Investments (continued):

Long-term investments consist of fixed income bonds with maturity dates greater than a year from the statement of financial position date and bearing interest at rates ranging from 0.51% to 7.18% (2024 - 1.25% to 8.35%), and Canadian and U.S. equities and investments in unit trusts.

3. Capital assets:

			2025	2024
	Cost	Accumulated amortization	Net book value	Net book value
Land	\$ 122,756	\$ —	\$ 122,756	\$ 122,756
Buildings	5,770,652	4,541,804	1,228,848	1,314,582
Computer equipment and software	1,098,650	707,918	390,732	175,153
Furniture and equipment	326,541	226,390	100,151	129,173
Leasehold improvements	390,302	54,126	336,176	374,804
	\$ 7,708,901	\$ 5,530,238	\$ 2,178,663	\$ 2,116,468

4. Deferred capital grants and donations:

Deferred capital grants and donations represent restricted capital funding received to purchase capital assets. Grants and donations are amortized on the same basis as the capital asset to which they relate. Changes in the deferred capital grants and donations balances during the year are as follows:

	2025	2024
Balance, beginning of year	\$ 609,617	\$ 676,367
Less amortization	46,166	66,750
Balance, end of year	\$ 563,451	\$ 609,617

ARTHRITIS SOCIETY CANADA/ SOCIÉTÉ D'ARTHRITE DU CANADA

Notes to Financial Statements (continued)

Year ended March 31, 2025

5. Deferred contributions:

Deferred contributions represent unspent resources, externally or internally restricted, for education, volunteer/community development, patient care, research purposes and restricted operating funds received in the current year or prior years that are related to subsequent periods. Changes in the deferred contribution balances during the year are as follows:

	2025			2024	
	Education	Patient care	Research	Total	Total
Balance, beginning of year	\$ 284,715	\$ 55	\$ 548,900	\$ 833,670	\$ 3,253,327
Funds received	459,288	—	2,024,715	2,484,003	892,995
Amount recognized as revenue	(511,526)	—	(314,593)	(826,119)	(3,312,652)
Balance, end of year	\$ 232,477	\$ 55	\$ 2,259,022	\$ 2,491,554	\$ 833,670

6. Annuity, life insurance and charitable remainder trust revenue:

As at March 31, 2025, the Society is the beneficiary of several annuities purchased by donors with original annuity contract amounts of \$65,000 (2024 - \$137,500). An annuity is established through an original donation of cash and the remaining donations being continuously invested. The cash donation and any realized beneficiary amounts are recorded as revenue when received. During 2025, nil (2024 - nil) was received in cash.

The Society is also the beneficiary of several life insurance policies purchased by donors. Revenue relating to these policies is recorded on a cash basis. The total death benefit relating to these policies outstanding as at March 31, 2025 amounted to \$432,034 (2024 - \$432,034).

The Society is also the beneficiary of several charitable remainder trusts. The donations are recorded as revenue when the cash is received. The trust amounts outstanding as at March 31, 2025 amounted to nil (2024 - nil). During 2025, \$4,400 (2024 - \$6,380) was received in cash and included in bequests and other planned giving.

ARTHRITIS SOCIETY CANADA/ SOCIÉTÉ D'ARTHRITE DU CANADA

Notes to Financial Statements (continued)

Year ended March 31, 2025

7. Change in non-cash operating working capital:

	2025	2024
Accounts receivable	\$ 225,364	\$ (344,599)
Prepaid expenses	104,070	(368,078)
Accounts payable and accrued liabilities	480,389	(55,159)
Deferred revenue	119,002	(209,711)
Research awards payable	(472,581)	(6,880)
	<u>\$ 456,244</u>	<u>\$ (984,427)</u>

8. Pension plan:

Certain of the employees of the Society are members of Arthritis Society Canada Pension Plan (the "Plan"), which is a defined contribution plan. Employer contributions made to the Plan during the fiscal year by the Society are reflected in the statement of financial activities and amounted to \$453,354 (2024 - \$416,540).

9. Research commitments:

The Society has approved research commitments for future years for which the recipients must meet certain milestone reporting requirements in order to achieve funds release, as follows:

2026	\$ 5,297,990
2027	3,084,415
2028	1,259,489
2029	67,500
	<u>\$ 9,709,394</u>

ARTHRITIS SOCIETY CANADA/ SOCIÉTÉ D'ARTHRITE DU CANADA

Notes to Financial Statements (continued)

Year ended March 31, 2025

10. Commitments:

The Society has entered into several operating lease commitments for office premises and office equipment. The minimum annual lease payments are as follows:

2026	\$ 559,762
2027	589,327
2028	542,795
2029	492,646
2030	534,698
Thereafter	1,987,299
	<hr/>
	\$ 4,706,527

11. Related party transactions:

During the year, \$265,047 (2024 - nil) was awarded to universities for the research of three members of the Society's National Board or the Integrated Scientific Advisory Committee and Medical Advisory Committee ("iSMAC"). The Society adheres to a rigorous peer-review and evaluation process for its grant competitions. This process follows a strict confidentiality and conflict of interest policy founded on transparency, fairness and accountability. Payments for awarded research grants are made to the university that the investigator is associated with and the disbursement of the funds is administered by the university.

ARTHRITIS SOCIETY CANADA/ SOCIÉTÉ D'ARTHRITE DU CANADA

Notes to Financial Statements (continued)

Year ended March 31, 2025

12. Bank indebtedness:

The Society obtained a revolving line demand facility on June 30, 2015, subsequently amended February 22, 2018, April 17, 2020, September 22, 2021, and April 8, 2024, of \$4,000,000 (2024 - \$1,500,000) available by way of Risk Based Pricing ("RBP") based on loans and letters of credit. The maximum amount of the facility increased from \$2,000,000 (2024 - \$1,500,000) to \$4,000,000 (2024 - \$2,000,000) on April 8, 2024 (2024 - September 22, 2021). The facility is due on demand and incurs interest calculated at the RBP rate plus 0.75% per annum. The amount outstanding under this facility at year end is nil (2024 - \$1,760,000). The facility is secured by a first ranking security interest in all personal property, and a collateral mortgage in the amount of up to \$4,000,000 (2024 - \$2,000,000) constituting a first fixed charge on the land and improvements located in Vancouver, British Columbia. The facility contains certain non-financial covenants which were met at March 31, 2025.

Total interest expense incurred by the Society during the year in relation to the revolving line demand facility was \$117,648 (2024 - \$47,815) and is included within administration expense.

13. Allocation of expenses:

The Society has allocated its common expenses consisting of certain salaries, benefits and other expenditures of the offices of the Chief Executive, Chief Scientific, Chief Development, and amortization of capital assets, to functional activities as follows:

	2025	2024
Research	\$ 195,805	\$ 187,008
Program and services	1,086,246	972,889
Building operation	93,042	112,208
Administration	135,954	188,899
Cost of raising funds	407,349	621,042
	<u>\$ 1,918,396</u>	<u>\$ 2,082,046</u>

ARTHRITIS SOCIETY CANADA/ SOCIÉTÉ D'ARTHRITE DU CANADA

Notes to Financial Statements (continued)

Year ended March 31, 2025

14. Risk management:

Risk management relates to the understanding and active management of risks associated with all areas of the business and the associated operating environment. The Society has not observed any material changes in credit, interest rate, liquidity, market or foreign exchange risk as compared to the prior year.

(a) Credit risk:

The Society's financial assets are cash and accounts receivable, both of which are subject to credit risk. The carrying amounts of financial assets on the statement of financial position represent the Society's maximum credit exposure at the statement of financial position date.

(b) Interest rate risk:

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. Changes in the prime interest rate will have a positive or negative impact on the Society's interest income. Such exposure will increase accordingly, should the Society maintain higher levels of investments in the future.

(c) Liquidity risk:

Liquidity risk is the risk that the Society will be unable to fulfill its obligations on a timely basis or at a reasonable cost. The Society manages its liquidity risk by monitoring its operating requirements. The Society prepares a budget and cash forecasts to ensure it has sufficient funds to fulfill its obligations. During 2021, the Board approved a policy requiring regular calculations of liquidity with a view to having six months of available operating expenses.

(d) Market risk:

Market risk arises as a result of trading in equity securities and fixed income securities. Fluctuations in the market expose the Society to a risk of loss. The Society mitigates this risk through controls to monitor and limit concentration levels.

ARTHRITIS SOCIETY CANADA/ SOCIÉTÉ D'ARTHRITE DU CANADA

Notes to Financial Statements (continued)

Year ended March 31, 2025

14. Risk management (continued):

(e) Foreign currency risk:

Foreign currency risk arises from gains and losses due to fluctuations in foreign currency exchange rates on the Society's foreign-denominated equity investments. The Society does not have significant transactions in foreign currencies or hold foreign currencies for a long period of time and, therefore, considers the exposure to foreign currency risk to be not significant.

15. Asset held for sale:

In July 2023, management committed to a plan to sell the property in Victoria, British Columbia. Accordingly, as at March 31, 2024, the property (land and building) was presented as an asset held for sale. A sale agreement was signed on October 29, 2024 and the property was sold on the agreed upon closing date, December 20, 2024.

During the year, the property was sold for net cash proceeds after sale costs of \$5,086,358. A gain on sale of property of \$4,703,302 has been disclosed in the statement of financial activities.

16. Alberta Charitable Fund-raising Act and Regulation:

Additional information to comply with the Disclosure Requirement of the Alberta Charitable Fund-raising Act and Regulation:

Disposition of contributions that is equal to or exceeds 10% of the gross contributions received were as follows:

Direct response	\$ 7,590,665
Rest of campaigns	7,878,619
Bequests	4,613,175
Investment and miscellaneous income	1,844,410
Support from government departments and agencies	5,930,795
	<hr/>
	\$ 27,857,664

ARTHRITIS SOCIETY CANADA/ SOCIÉTÉ D'ARTHRITE DU CANADA

Notes to Financial Statements (continued)

Year ended March 31, 2025

16. Alberta Charitable Fund-raising Act and Regulation (continued):

\$3,175,255 was paid as remuneration to employees whose principal duties involve fundraising.

\$718,306 was paid as remuneration to the fund-raising business, including any expenses or fees paid by the charitable organization on behalf of the fund-raising business or as reimbursements to the fund-raising business.